Tusamitamab ravtansine

DB17448InvestigationalProtein Based Therapies

Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5).

Mechanism: Pharmacologically active on Cell adhesion molecule CEACAM5
Curator reviewed
Also known as: Maytansin-loaded anti-ceacam5 mab
Code names: SAR-408701

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tusamitamab ravtansine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.